X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

By Nicole Longo  |    December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...   Read More

Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements

By Nicole Longo  |    December 15, 2020
In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the...   Read More

PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients

By Nicole Longo  |    November 2, 2020
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways...   Read More

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients

By Nicole Longo  |    October 23, 2020
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...   Read More

Growth in 340B program has not translated to improvements for patients

By Nicole Longo  |    October 5, 2020
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program....   Read More

New GAO report: Some hospitals participating in 340B may not be eligible for the program

By Nicole Longo  |    January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability...   Read More

Nearly 50% of brand medicine spending goes to the supply chain and others

By Holly Campbell  |    January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...   Read More

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

Study finds hospitals continue to mark up medicines up to 500% of their cost

By Holly Campbell  |    July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....   Read More

Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals

By Nicole Longo  |    May 16, 2019
There has been broad acknowledgement in Congress and by the Administration, as well as by patient groups and some hospitals, that the 340B program is not working as Congress intended. Yet little...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates